Bifogade filer
PDF
Kurs & Likviditet
+2,44%
|
1,10 MSEK
Kursutveckling och likviditet under dagen för detta pressmeddelande
Kalender
| 2025-02-07 | Bokslutskommuniké 2024 |
| 2024-10-25 | Kvartalsrapport 2024-Q3 |
| 2024-07-12 | Kvartalsrapport 2024-Q2 |
| 2024-04-24 | Kvartalsrapport 2024-Q1 |
| 2024-04-10 | Ordinarie utdelning EPIS B 0.00 SEK |
| 2024-04-09 | Årsstämma 2024 |
| 2024-02-09 | Bokslutskommuniké 2023 |
| 2023-10-27 | Kvartalsrapport 2023-Q3 |
| 2023-07-14 | Kvartalsrapport 2023-Q2 |
| 2023-05-03 | Ordinarie utdelning EPIS B 0.00 SEK |
| 2023-05-02 | Årsstämma 2023 |
| 2023-04-28 | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | Bokslutskommuniké 2022 |
| 2022-11-16 | Kvartalsrapport 2022-Q3 |
| 2022-07-15 | Kvartalsrapport 2022-Q2 |
| 2022-04-29 | Kvartalsrapport 2022-Q1 |
| 2022-04-05 | Ordinarie utdelning EPIS B 0.00 SEK |
| 2022-04-04 | Årsstämma 2022 |
| 2022-02-11 | Bokslutskommuniké 2021 |
| 2021-10-29 | Kvartalsrapport 2021-Q3 |
| 2021-07-16 | Kvartalsrapport 2021-Q2 |
| 2021-05-11 | Ordinarie utdelning EPIS B 0.00 SEK |
| 2021-05-10 | Årsstämma 2021 |
| 2021-04-29 | Kvartalsrapport 2021-Q1 |
| 2021-02-19 | Bokslutskommuniké 2020 |
| 2020-10-23 | Kvartalsrapport 2020-Q3 |
| 2020-07-17 | Kvartalsrapport 2020-Q2 |
| 2020-04-24 | Kvartalsrapport 2020-Q1 |
| 2020-04-03 | Ordinarie utdelning EPIS B 0.00 SEK |
| 2020-04-02 | Årsstämma 2020 |
| 2020-03-10 | Extra Bolagsstämma 2020 |
| 2020-02-07 | Bokslutskommuniké 2019 |
| 2019-10-25 | Kvartalsrapport 2019-Q3 |
| 2019-07-19 | Kvartalsrapport 2019-Q2 |
| 2019-05-07 | Extra Bolagsstämma 2019 |
| 2019-04-26 | Kvartalsrapport 2019-Q1 |
| 2019-04-09 | Ordinarie utdelning EPIS B 0.00 SEK |
| 2019-04-08 | Årsstämma 2019 |
| 2019-02-08 | Bokslutskommuniké 2018 |
| 2018-10-26 | Kvartalsrapport 2018-Q3 |
| 2018-07-20 | Kvartalsrapport 2018-Q2 |
| 2018-04-27 | Kvartalsrapport 2018-Q1 |
| 2018-04-10 | Ordinarie utdelning EPIS B 0.00 SEK |
| 2018-04-09 | Årsstämma 2018 |
| 2018-02-23 | Bokslutskommuniké 2017 |
| 2017-11-10 | Kvartalsrapport 2017-Q3 |
| 2017-08-18 | Kvartalsrapport 2017-Q2 |
| 2017-05-23 | Ordinarie utdelning EPIS B 0.00 SEK |
| 2017-05-22 | Årsstämma 2017 |
| 2017-05-15 | Kvartalsrapport 2017-Q1 |
| 2017-02-24 | Bokslutskommuniké 2016 |
| 2017-02-20 | Extra Bolagsstämma 2017 |
| 2016-11-04 | Kvartalsrapport 2016-Q3 |
| 2016-08-19 | Kvartalsrapport 2016-Q2 |
| 2016-05-25 | Ordinarie utdelning EPIS B 0.00 SEK |
| 2016-05-24 | Årsstämma 2016 |
| 2016-05-17 | Kvartalsrapport 2016-Q1 |
| 2016-02-23 | Bokslutskommuniké 2015 |
| 2015-11-06 | Kvartalsrapport 2015-Q3 |
| 2015-08-21 | Kvartalsrapport 2015-Q2 |
| 2015-05-07 | Ordinarie utdelning EPIS B 0.00 SEK |
| 2015-05-06 | Kvartalsrapport 2015-Q1 |
| 2015-05-06 | Årsstämma 2015 |
| 2015-02-20 | Bokslutskommuniké 2014 |
| 2014-11-07 | Kvartalsrapport 2014-Q3 |
| 2014-08-22 | Kvartalsrapport 2014-Q2 |
| 2014-06-04 | Ordinarie utdelning EPIS B 0.00 SEK |
| 2014-06-03 | Årsstämma 2014 |
| 2014-05-09 | Kvartalsrapport 2014-Q1 |
| 2014-02-21 | Bokslutskommuniké 2013 |
| 2014-02-12 | Extra Bolagsstämma 2014 |
| 2013-11-06 | Kvartalsrapport 2013-Q3 |
| 2013-08-22 | Kvartalsrapport 2013-Q2 |
| 2013-05-03 | Ordinarie utdelning EPIS B 0.00 SEK |
| 2013-05-03 | Kvartalsrapport 2013-Q1 |
| 2013-05-02 | Årsstämma 2013 |
| 2013-04-03 | Extra Bolagsstämma 2013 |
| 2013-02-21 | Bokslutskommuniké 2012 |
| 2012-11-21 | Kvartalsrapport 2012-Q3 |
| 2012-08-22 | Kvartalsrapport 2012-Q2 |
| 2012-06-04 | Årsstämma 2012 |
| 2012-05-04 | Kvartalsrapport 2012-Q1 |
| 2012-02-21 | Bokslutskommuniké 2011 |
| 2011-11-21 | Kvartalsrapport 2011-Q3 |
| 2011-08-22 | Kvartalsrapport 2011-Q2 |
| 2011-07-20 | Split EPIS B 6:1 |
| 2011-06-30 | Årsstämma 2011 |
| 2011-05-21 | Kvartalsrapport 2011-Q1 |
| 2011-05-13 | Extra Bolagsstämma 2011 |
| 2011-05-02 | Kvartalsrapport 2011-Q1 |
| 2011-02-18 | Bokslutskommuniké 2010 |
| 2010-08-30 | Extra Bolagsstämma 2010 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2022-07-15 08:30:00
- 72% growth in the number of active customers during the quarter - Episurf is experiencing a faster adoption and increased acceptance for the Episealer® technology
- In six months 2022, Episurf has already exceeded the full year 2021 figure for the number of active customers
- 42% growth in gross order intake and a strong cash position
"The main priority in our commercial efforts right now is to grow the user base, and we are clearly seeing that our ability to generate new customers is better than ever. In fact, during the first two quarters of 2022, we have already had as many customers (66) as we had for the full year 2021. Volumes will increase with each customer as pandemic-related backlogs are worked through and when user experience from the Episealer® increases", says Pål Ryfors, CEO Episurf Medical.
Second quarter 2022 compared to 2021, Group- Gross order intake amounted to SEK 2.0m (1.4)
- Order book amounted to SEK 1.5m (1.3)
- Group net sales amounted to SEK 1.9m (2.0)
- Loss for the period amounted to SEK -19.4m (-17.7)
- Earnings per share amounted to SEK -0.07(-0.08)
- Gross order intake amounted to SEK 3.6m (3.6)
- Group net sales amounted to SEK 3.4m (3.6)
- Loss for the period amounted to SEK -35.8m (-34.4)
- Earnings per share amounted to SEK -0.13(-0.16)
- Promising results from comparative study with Episealer® were accepted for presentation at German orthopaedic congress
- Episurf Medical submitted follow-up 510(k) application for Episealer® Patellofemoral System that is now under substantive review at the US FDA
- Prospective investigator-initiated study for 2 years' follow-up of Episealer® Talus patient initiated
- First knee implant Episealer® surgery was planned in Saudi Arabia, and India were planned
- First Episealer® Talus surgery performed in Portugal and Belgium
- 5-year follow-up data presented at several clinical congresses
- Presentation by Prof Karl Eriksson about the Episealer® Knee technology and clinical results at the 5[th] International Conference on Meniscus Science and Surgery in Luxembourg
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com (pal.ryfors@episurf.com)